Kristin K. Zorn, MD | Authors

RUSH UNIVERSITY MEDICAL CENTER

6414 N PAULINA ST # 201

Articles

PARP Inhibition in Epithelial Ovarian Cancer: High Hopes Undergo a Reality Check

February 15, 2012

This article reviews the trials that have been conducted with PARP inhibitors in epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, and places the impact of those results in the larger context of PARP inhibitor development.

Challenges to the Paclitaxel/Carboplatin Algorithm in Ovarian Cancer Treatment

July 15, 2010

After years of maintaining the status quo in ovarian cancer treatment, a number of recent advances have challenged the paradigm based on intravenous (IV) taxane and platinum as the therapy of choice for advanced ovarian cancer. These new data are summarized concisely by Liu and Matulonis in this issue.